Evidence map›Paper›PMID 42346255›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.

Nagham Youssef, Maha Hameed, Shebli Atrash, Barry Paul, Abdullah Mohammad Khan, Hira Shaikh, Christopher Strouse, Andrew Vegel, Zena Chahine, Anita Mazloom and 15 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Nagham YoussefLevine Cancer Center, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28204, USA.
Maha HameedInternal Medicine Department, Florida State University, Sarasota, FL 34236, USA.ORCID 0000-0001-8066-4584
Shebli AtrashLevine Cancer Center, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28204, USA.ORCID 0000-0003-4547-7534
Barry PaulLevine Cancer Center, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC 28204, USA.
Abdullah Mohammad KhanDivision of Hematology, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-2166-2583
Hira ShaikhDivision of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-5604-4166
Christopher StrouseDivision of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA 52242, USA.
Andrew VegelDivision of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA 52242, USA.
Zena ChahineDivision of Bone Marrow Transplant, University of Kentucky, Lexington, KY 40536, USA.ORCID 0009-0003-1247-3526
Anita MazloomDivision of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.ORCID 0009-0009-7899-7078
Muhammad Salman FaisalDivision of Bone Marrow Transplant, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Taha Al-JuhaishiDivision of Bone Marrow Transplant, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Omar AlkharabshehDivision of Hematology and Oncology, University of Cincinnati, Cincinnati, OH 45267, USA.ORCID 0000-0002-5299-4233
Anas ZayadDepartment of Internal Medicine, Hamad Medical Corporation, Doha P.O. Box 3050, Qatar.ORCID 0009-0006-7537-0112
Carmel AwadallahDivision of Internal Medicine, St John's Episcopal Hospital, Far Rockaway, NY 11691, USA.
Jordan SnyderDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.
Zahra MahmoudjafariDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-3168-2521
Muhammad Umair MushtaqDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.
Jeries KortDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0001-9182-3931
Alma HabibDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.
Forat LutfiDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-9699-3080
Al-Ola AbdallahDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-6603-185X
Mansi ShahDivision of Hematology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Prerna MewawallaDivision of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA 15224, USA.ORCID 0009-0008-7464-6898
Sarah WaheedDivision of Hematology and Bone Marrow Transplant, Johns Hopkins Hospital, Baltimore, MD 21231, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell maturation antigen (BCMA)-directed therapies (BDTs) have transformed relapsed/refractory multiple myeloma treatment, but optimal post-failure sequencing remains undefined. We evaluated real-world outcomes from three retrospective, multicenter analyses. Study 1 compared BCMA CAR-T and BCMA T-cell engagers (TCEs) in BDT-exposed patients (

Indexed as

B-Cell Maturation AntigenImmunotherapy, AdoptiveMultiple MyelomaNeoplasm Recurrence, LocalAgedFemaleHumansMaleMiddle AgedRetrospective StudiesUnited StatesB-Cell Maturation Antigenantigen switchingBCMA-directed therapybispecific antibodiesCAR-T cell therapymultiple myelomareal-world outcomesrelapsed/refractory multiple myeloma (RRMM)talquetamabteclistamabtreatment sequencing

Identifiers

PMID42346255
PMCPMC13298005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.